Sounders training center tabbed as base camp option for FIFA World CupFDA Approves Symvess for Treatment of Extremity Vascular Trauma
DAT: November truckload volumes lagged robust October
SLU schedules fall graduationsDid Joe Rogan’s Trump interview trigger an alien invasion? Viral theory explainedUSA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights , underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases . This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care—particularly delays in screenings, diagnoses, and treatments—have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cardiff Oncology, Inc. (NASDAQ: CRDF), Personalis, Inc. (NASDAQ: PSNL), Tempus AI, Inc. (NASDAQ: TEM), and Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031 —a clear indicator of oncology's rapid growth and critical importance. Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers, which were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025 . "We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer," said Tom Heineman , M.D., Ph.D., Chief Medical Officer of Oncolytics . "Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devasting diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients." Oncolytics will present two key data sets from the GOBLET study, with preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab presented in Poster Session C on January 25, 2025 , from 7:00 to 7:55 a.m. PT . Additionally, results from the safety run-in phase for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, with and without atezolizumab will be presented in Poster Session B on January 24, 2025 , from 11:30 a.m. to 1:00 p.m. PT . Both abstracts will be available on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025 . CONTINUED... Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024 , data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient's tumor scan. "We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial," said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology . "Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses." Personalis, Inc. (NASDAQ: PSNL), a developer of advanced cancer genomic tests and analytics, and Tempus AI, Inc. (NASDAQ: TEM), an AI-powered healthcare technology company, recently announced they've expanded their commercial relationship. Both companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. "While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products," said Chris Hall , CEO of Personalis . "We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity." Under this expanded relationship, Tempus will be enabled to offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study. Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), a commercial-stage immunotherapy and targeted oncology company focused on novel treatments for patients with solid tumor cancers, recently announced that the FDA approved its UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. "[This] FDA approval of UNLOXCYT – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced cSCC," said James Oliviero , President and CEO of Checkpoin t. "This approval marks Checkpoint's transformation to a commercial-stage company, with the opportunity to compete in a U.S. market estimated to exceed $1 billion annually, where we believe UNLOXCYT offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than programmed death receptor-1 (PD-1), to release the inhibitory effects of PD-L1 on the anti-tumor immune response. Additionally, UNLOXCYT has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), another potential differentiating feature of the drug compared to existing marketed therapies for patients with cSCC." Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: USA NEWS GROUP info@usanewsgroup.com (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. View original content: https://www.prnewswire.com/news-releases/oncology-advancements-accelerate-amid-rising-early-onset-cancer-diagnoses-302337555.html SOURCE USA News GroupMLC expresses concern over politics of hatred, decline in tolerance
After rough start under coach Mike Macdonald, the Seahawks’ defense has become a strengthIndia key in NTT's strategy in APAC: CEO
NoneNew Delhi: Delhi govt will soon start using artificial intelligence (AI) to verify documents uploaded by city residents to avail of various online services related to the transport department. It will also solve people's queries through a virtual assistant. The use of technology will reduce the turnaround time, eliminate the possibility of any oversight and ensure that the documents such as driving licences, permits and registration certificates are issued faster, officials said. According to officials, there are 47 services of the transport department that have been completely transitioned to a faceless delivery mode, and nearly 30 lakh applicants have so far benefited from it. The number, they said, was expected to increase significantly over the next decade. Currently, the system is managed manually at the backend, and the staff review and approve each application for the different services. "By introducing the power of AI to assist applicants and staff for document verification, the turnaround time can be improved. The use of AI as a virtual assistant to the applicants' queries will improve the quality of service and avoid visits to the office," said an official, adding that an AI-powered dashboard , assisted with a virtual assistant, provides a better interface and information for decision-making and improves the quality of services. Another official said that the transport department had floated a request for proposal to engage a technology firm to develop the AI-based system. The AI-powered tool will detect any discrepancy with citizen documents in real-time based on the upload of the document on the Vahan and Sarthi portals. In case the document is not legible to read, the system would enhance it to make it readable. "The solution will be developed, deployed and tested for 13 services initially in phase 1, and will be extended to cover the remaining 34 subsequently. It will verify whether the mandatory documents are attached, enhance the readability and clarity of attached documents, and read relevant fields from them. It will also detect blurred or unclear photos, and in case of rejection, it will highlight the abnormalities," said the official. Officials said the virtual assistant would be designed in a way that it would be capable of answering and assisting citizen queries related to services within its scope, required documents, steps to avail services, estimated turnaround times, and application status in both English and Hindi languages. "The dashboard will be voice-and text-enabled, and provide RTO-wise service status, including total applications received and disposed of, turnaround times, pendency, its reasons, and other key insights to enhance operational efficiency," said the official. Stay updated with the latest news on Times of India . Don't miss daily games like Crossword , Sudoku , and Mini Crossword .
Kingsport, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Kingsport, Tennessee - Pink Duck Plumbing , a new and dynamic plumbing company, is making waves in the Tri-Cities region with its fresh approach to customer service and plumbing excellence. Locally owned and operated by co-owners Derek and Brian, Pink Duck Plumbing has quickly gained recognition as one of the leading plumbing companies in the Kingsport and Johnson City areas. From drain cleaning to water heater repairs, the company's comprehensive suite of plumbing solutions is backed by a commitment to reliability, customer satisfaction, and community impact. At Pink Duck Plumbing, the mission goes far beyond fixing pipes. The company is built on offering extraordinary customer experiences, fostering a life-giving work culture, and delivering top-tier plumbing solutions. This ethos is deeply rooted in the values of co-owners Derek and Brian, who are dedicated to setting new standards for the plumbing industry. "We started Pink Duck Plumbing because we saw an opportunity to do things differently," said Derek and Brian in a joint statement. "Our goal is to combine expert plumbing services with an unwavering commitment to customer care. We believe in treating every customer like family and ensuring that every service call is handled with professionalism, respect, and excellence. The support we've received from the Kingsport and Johnson City communities since launching this business has been overwhelming, and we are truly grateful. It inspires us to keep striving for better every day." Pink Duck Plumbing specializes in a wide range of plumbing services, including: Drain Cleaning: Efficient solutions to clear blockages and restore proper flow. Water Line Repairs and Replacements: Expert handling of critical water supply infrastructure. Water Heater Repairs and Replacements: Keeping homes warm and comfortable with reliable hot water solutions. Plumbing Installations and Repairs: Comprehensive services for new installations or maintenance of existing systems. The company's team of skilled and experienced plumbers ensures that each job, no matter how big or small, is completed to the highest standards. Their dedication to quality workmanship and prompt service has earned them a reputation as a trusted name in the region. Pink Duck Plumbing is more than just a business-it's a community partner. Derek and Brian's passion for giving back is evident in their commitment to creating a positive impact not only for their customers but also for their team. The company fosters a life-giving work culture that prioritizes the well-being of its employees, empowering them to deliver the best possible service. "Our philosophy is simple: happy team members make happy customers," said Derek. "By creating an environment where our team feels valued and supported, we can focus on providing the extraordinary experiences our customers deserve." This community-driven approach has resonated with the people of Kingsport and Johnson City, who have embraced Pink Duck Plumbing with enthusiasm. Derek and Brian attribute their early success to this outpouring of local support. With a strong foundation in place, Pink Duck Plumbing has ambitious plans for the future. The company aims to continue raising the bar for plumbing services in the Tri-Cities area by investing in innovative technology, expanding its service offerings, and deepening its community involvement. "Every day is an opportunity to make a difference," said Brian. "Whether it's through solving a plumbing problem or supporting a local cause, we're here to leave a positive mark on this community. The Tri-Cities region has been so good to us, and we are committed to giving back in every way we can." For reliable, top-quality plumbing services in Kingsport, Johnson City, and beyond, trust Pink Duck Plumbing to deliver extraordinary results. To learn more about their services or schedule an appointment, visit their website at https://www.pinkduckplumbing.com or call (423) 732-3825. About Pink Duck Plumbing Pink Duck Plumbing is a locally owned and operated plumbing company serving the Tri-Cities region, including Kingsport and Johnson City, Tennessee. Founded with a mission to transform the plumbing experience, the company offers expert services ranging from drain cleaning to water heater replacements. Guided by a vision of extraordinary customer service and community impact, Pink Duck Plumbing is setting a new standard in the industry. ### For more information about Pink Duck Plumbing, contact the company here: Pink Duck Plumbing Brian Fitzgerald (423) 732-3825 [email protected] 104 Dillow Cir Kingsport, TN 37663 CONTACT: Brian Fitzgerald
ALLEN PARK -- With another game right around the corner, two starters and another key piece for the Detroit Lions are facing an uphill climb to be ready for Thanksgiving. The Detroit Lions (10-1) just beat the Indianapolis Colts on the road. But they are already back home and starting the next week of preparation. They’ll host the Chicago Bears in their annual Thanksgiving classic game from Ford Field.
Maverick McNealy birdies the last hole at Sea Island to finally become PGA Tour winner
Maverick McNealy birdies the last hole at Sea Island to finally become PGA Tour winnerehrlif Introduction Enbridge ( NYSE: ENB ) stock performs good as it has delivered a total 10.3% return to investors since my previous bullish call . Developments around the company are quite positive and there is quite an ambitious and well-diversified pipeline Analyst’s Disclosure: I/we have a beneficial long position in the shares of ENB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.If I could only keep 5 UK stocks from my portfolio I’d save these
Cyber Monday shoppers expected to set a record on biggest day for online shopping
Share Tweet Share Share Email A decade ago, working from home was a rare anomaly, treated as a superfluous novelty by most individuals and organizations in the professional world. Today, most people with jobs that can be done remotely work remotely at least part of the time – and many businesses, especially those in the tech space, operate fully remotely. It seems that remote work is here to stay, thanks in part to the ever-increasing accessibility and power of technology. But how are companies going to evolve from here as these technologies grow in availability and sophistication? The Ever-Increasing Power of Technology Technology is the foundational building block that has allowed remote work to grow as popular as it has. Today, we have access to hardware and software that allows us to communicate, collaborate, and accomplish a wide variety of tasks, regardless of where we are. We have chat platforms and video conferencing platforms. We have robust management systems and project tracking tools. We have monitoring and productivity tools to keep people on point. We even have health and wellness apps to make sure that working from home isn’t getting the better of us. Perhaps, then, it’s no surprise that tech companies seem to be some of the most ardent supporters of remote work overall. Not only do they understand the power of technology for connecting people in remote locations, but they may also play a role in developing and maintaining it. The Pros and Cons of Remote Work Still, there are both pros and cons associated with working remotely. For example, these are just some of the benefits: Lower office expenses. If you work remotely, you don’t need an office building. If only part of your staff works remotely, you’ll need only a relatively small office building. This can help you greatly reduce office expenses, improving your profitability in the long run. And if you currently own commercial real estate, you may be able to rent or sublet it to other businesses as a secondary stream of income; it’s also possible to manage commercial real estate remotely , but this isn’t always a good organizational fit. Higher productivity. Many organizations with remote or hybrid work benefit from higher productivity. When people have more flexibility in how they approach work and more freedom on an individual level, they tend to get more done. Higher morale. Similarly, remote work environments often promote higher morale. People are happier working for organizations that grant them autonomy and flexibility, and they’re much more likely to stay there. A bigger talent pool. When you operate a company remotely or mostly remotely, you open the doors to candidates who would otherwise be unable to work for you. With a bigger talent pool, you can find better fits for your open positions. Increased retention. For these reasons and others, remote and hybrid workplaces benefit from increased employee retention. Not only does this reduce costs, but it also increases consistency and continuity within your organization. Sustainability. As you might imagine, remote businesses are greener and more sustainable. With fewer people driving to and from work, there will be fewer greenhouse gas emissions. These are some of the drawbacks: Detachment. Work culture is important , but it isn’t easy to maintain in a remote environment. When you have people living in different places, interacting with each other less frequently, you tend to lose the cohesiveness of your culture. Lack of transparency. Even with robust employee monitoring and productivity tools in place, your organization may suffer from a lack of transparency. You may not know exactly what your employees are working on or exactly how they’re spending their time, leading to gaps in knowledge and collaborative potential. Less information. It’s often harder for managers and supervisors to do their jobs in remote environments. It can also be harder for decision makers, who need to incorporate many independent pieces of information to make effective decisions. With less information available, every organization suffers. Loneliness and isolation. While many people benefit from higher morale and higher productivity when working from home, some people suffer from increased loneliness and isolation. Even people who work well by themselves need occasional in-person socialization to feel connected with others. Higher stress. Studies indicate that broadly, remote work is associated with lower stress levels , but for some workers, the opposite is true. They may not be happy or comfortable in their home environment, or they may simply work better in a traditional office setting. In any case, for these types of workers, working remotely is a source of additional stress. Technology and Company Evolution: Possibilities for the Future So where does remote work go from here? For starters, we need to recognize that technology is only going to become more advanced and better capable of connecting us remotely. With so many companies offering remote work to at least some of their people at least some of the time, the demand for better remote collaboration and communication tools is almost constantly growing. And, of course, with rising demand, there’s likely to be a rising number of entrepreneurs and innovators trying to meet that demand. So, in some ways, the advantages of remote work are almost certainly going to continue increasing, with the disadvantages increasingly being compensated for. But how will businesses adapt to these circumstances, and will the trend of remote work remain indefinitely? These are harder questions to answer. It’s very unlikely that all businesses will go fully remote, or even strive to be fully remote, given the persistent disadvantages of remote work and, to a lesser extent, stubborn mindsets in professional industries. But because the advantages of remote work are only growing, it’s also unlikely that any business that has dabbled in remote work will ever go back to being fully in-person. Accordingly, the most popular approach will likely be a hybrid one. As technologies that enable remote work become more advanced, companies will likely discover and reinforce strategies that enable “the best of both worlds,” with options for both remote and in-person work. Related Items: Remote work , work from home Share Tweet Share Share Email Recommended for you Want To Work Remotely? Then You Need To Develop These Skills Managing gen z remotely: tech challenges and solutions How gen z is redefining remote work CommentsTrump's eldest son emerges as key voice influencing cabinet picks
Mixed reactions to Tjibaou's election to New Caledonia pro-independence partyHoliday travelers, football fans hampered by year's first snowfallAvior Wealth Management LLC boosted its position in shares of Timothy Plan US Large/Mid Cap Core ETF ( NYSEARCA:TPLC – Free Report ) by 16.4% in the third quarter, Holdings Channel.com reports. The firm owned 4,012 shares of the company’s stock after purchasing an additional 564 shares during the period. Avior Wealth Management LLC’s holdings in Timothy Plan US Large/Mid Cap Core ETF were worth $177,000 as of its most recent SEC filing. Several other hedge funds also recently bought and sold shares of the company. Aptus Capital Advisors LLC bought a new stake in Timothy Plan US Large/Mid Cap Core ETF in the second quarter worth $41,000. Mather Group LLC. bought a new position in shares of Timothy Plan US Large/Mid Cap Core ETF in the 2nd quarter valued at approximately $42,000. International Assets Investment Management LLC acquired a new stake in Timothy Plan US Large/Mid Cap Core ETF in the 2nd quarter worth approximately $44,000. Larson Financial Group LLC boosted its position in Timothy Plan US Large/Mid Cap Core ETF by 27.8% during the second quarter. Larson Financial Group LLC now owns 2,797 shares of the company’s stock worth $113,000 after purchasing an additional 608 shares during the period. Finally, Values First Advisors Inc. acquired a new position in Timothy Plan US Large/Mid Cap Core ETF during the third quarter valued at approximately $194,000. Timothy Plan US Large/Mid Cap Core ETF Trading Up 1.0 % Shares of Timothy Plan US Large/Mid Cap Core ETF stock opened at $45.89 on Friday. The firm has a fifty day simple moving average of $44.14 and a 200-day simple moving average of $42.32. The stock has a market capitalization of $257.01 million, a price-to-earnings ratio of 21.29 and a beta of 0.87. Timothy Plan US Large/Mid Cap Core ETF has a 1-year low of $35.65 and a 1-year high of $45.90. Timothy Plan US Large/Mid Cap Core ETF Cuts Dividend Timothy Plan US Large/Mid Cap Core ETF Profile ( Free Report ) The Timothy Plan US Large\u002FMid Cap Core ETF (TPLC) is an exchange-traded fund that mostly invests in large cap equity. The fund tracks a volatility-weighted index of US large-cap stocks screened for Christian values. TPLC was launched on Apr 29, 2019 and is managed by Timothy. Recommended Stories Want to see what other hedge funds are holding TPLC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Timothy Plan US Large/Mid Cap Core ETF ( NYSEARCA:TPLC – Free Report ). Receive News & Ratings for Timothy Plan US Large/Mid Cap Core ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Timothy Plan US Large/Mid Cap Core ETF and related companies with MarketBeat.com's FREE daily email newsletter .